ES2658953T3 - Combinaciones y usos de los mismos - Google Patents
Combinaciones y usos de los mismos Download PDFInfo
- Publication number
- ES2658953T3 ES2658953T3 ES13766523.8T ES13766523T ES2658953T3 ES 2658953 T3 ES2658953 T3 ES 2658953T3 ES 13766523 T ES13766523 T ES 13766523T ES 2658953 T3 ES2658953 T3 ES 2658953T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- sequence
- melphalan
- antibody
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705172P | 2012-09-25 | 2012-09-25 | |
| US201261705172P | 2012-09-25 | ||
| US201361774595P | 2013-03-08 | 2013-03-08 | |
| US201361774595P | 2013-03-08 | ||
| PCT/EP2013/069858 WO2014048921A1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2658953T3 true ES2658953T3 (es) | 2018-03-13 |
Family
ID=49237209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13766523.8T Active ES2658953T3 (es) | 2012-09-25 | 2013-09-24 | Combinaciones y usos de los mismos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9579378B2 (enExample) |
| EP (1) | EP2900232B1 (enExample) |
| JP (1) | JP6426093B2 (enExample) |
| KR (1) | KR102171669B1 (enExample) |
| CN (1) | CN104684552B (enExample) |
| AU (1) | AU2013322806C1 (enExample) |
| BR (1) | BR112015006731A2 (enExample) |
| CA (1) | CA2885792C (enExample) |
| DK (1) | DK2900232T3 (enExample) |
| ES (1) | ES2658953T3 (enExample) |
| HR (1) | HRP20171964T1 (enExample) |
| HU (1) | HUE036518T2 (enExample) |
| IL (1) | IL237926B (enExample) |
| LT (1) | LT2900232T (enExample) |
| MX (1) | MX368288B (enExample) |
| NZ (1) | NZ706147A (enExample) |
| PL (1) | PL2900232T3 (enExample) |
| PT (1) | PT2900232T (enExample) |
| RU (1) | RU2650618C2 (enExample) |
| SG (1) | SG11201502163QA (enExample) |
| WO (1) | WO2014048921A1 (enExample) |
| ZA (1) | ZA201501980B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| CN108699161B (zh) * | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| IL317328A (en) * | 2018-12-14 | 2025-01-01 | Morphosys Ag | Antibody formulations |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| ES2541436T3 (es) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| AU2007302448C1 (en) | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| NZ607473A (en) | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US20140221319A1 (en) | 2011-06-29 | 2014-08-07 | Mayo Foundation For Medical Education And Research | Small Molecule CD38 Inhibitors and Methods of Using Same |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
-
2013
- 2013-09-24 ES ES13766523.8T patent/ES2658953T3/es active Active
- 2013-09-24 EP EP13766523.8A patent/EP2900232B1/en active Active
- 2013-09-24 HR HRP20171964TT patent/HRP20171964T1/hr unknown
- 2013-09-24 CN CN201380050577.7A patent/CN104684552B/zh active Active
- 2013-09-24 PT PT137665238T patent/PT2900232T/pt unknown
- 2013-09-24 SG SG11201502163QA patent/SG11201502163QA/en unknown
- 2013-09-24 AU AU2013322806A patent/AU2013322806C1/en active Active
- 2013-09-24 KR KR1020157007554A patent/KR102171669B1/ko active Active
- 2013-09-24 NZ NZ706147A patent/NZ706147A/en unknown
- 2013-09-24 PL PL13766523T patent/PL2900232T3/pl unknown
- 2013-09-24 RU RU2015110981A patent/RU2650618C2/ru active
- 2013-09-24 WO PCT/EP2013/069858 patent/WO2014048921A1/en not_active Ceased
- 2013-09-24 LT LTEP13766523.8T patent/LT2900232T/lt unknown
- 2013-09-24 DK DK13766523.8T patent/DK2900232T3/en active
- 2013-09-24 HU HUE13766523A patent/HUE036518T2/hu unknown
- 2013-09-24 CA CA2885792A patent/CA2885792C/en active Active
- 2013-09-24 MX MX2015003589A patent/MX368288B/es active IP Right Grant
- 2013-09-24 US US14/430,801 patent/US9579378B2/en active Active
- 2013-09-24 JP JP2015532454A patent/JP6426093B2/ja active Active
- 2013-09-24 BR BR112015006731A patent/BR112015006731A2/pt not_active Application Discontinuation
-
2015
- 2015-03-23 ZA ZA2015/01980A patent/ZA201501980B/en unknown
- 2015-03-24 IL IL237926A patent/IL237926B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| HK1210949A1 (en) | 2016-05-13 |
| JP2015530399A (ja) | 2015-10-15 |
| EP2900232A1 (en) | 2015-08-05 |
| HRP20171964T1 (hr) | 2018-02-23 |
| MX2015003589A (es) | 2015-08-12 |
| PT2900232T (pt) | 2018-02-09 |
| AU2013322806A1 (en) | 2015-04-09 |
| IL237926B (en) | 2020-04-30 |
| KR20150090030A (ko) | 2015-08-05 |
| IL237926A0 (en) | 2015-05-31 |
| MX368288B (es) | 2019-09-27 |
| HUE036518T2 (hu) | 2018-07-30 |
| DK2900232T3 (en) | 2018-02-05 |
| CA2885792C (en) | 2021-09-28 |
| AU2013322806C1 (en) | 2018-03-08 |
| KR102171669B1 (ko) | 2020-10-30 |
| RU2650618C2 (ru) | 2018-04-16 |
| AU2013322806B2 (en) | 2017-11-30 |
| CN104684552A (zh) | 2015-06-03 |
| SG11201502163QA (en) | 2015-04-29 |
| LT2900232T (lt) | 2018-02-26 |
| WO2014048921A1 (en) | 2014-04-03 |
| RU2015110981A (ru) | 2016-11-20 |
| US9579378B2 (en) | 2017-02-28 |
| ZA201501980B (en) | 2017-11-29 |
| BR112015006731A2 (pt) | 2017-07-04 |
| US20150238603A1 (en) | 2015-08-27 |
| CA2885792A1 (en) | 2014-04-03 |
| EP2900232B1 (en) | 2017-11-15 |
| PL2900232T3 (pl) | 2018-05-30 |
| JP6426093B2 (ja) | 2018-11-28 |
| CN104684552B (zh) | 2018-08-07 |
| NZ706147A (en) | 2018-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7562296B2 (ja) | がんの処置のための併用治療 | |
| ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| CN115087665A (zh) | 用于靶向递送治疗剂的工程化血小板 | |
| ES2694239T3 (es) | Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD) | |
| AU2022298639C1 (en) | Diacylglyercol kinase modulating compounds | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2001247459A (ja) | 癌の組み合わせ療法 | |
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| TW201024310A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
| AU2020317239A1 (en) | Anti-neoplastic combined pharmaceutical composition and application thereof | |
| JP2021530444A (ja) | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 | |
| KR20160079918A (ko) | Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
| JP2011520846A (ja) | 多発性骨髄腫の治療 | |
| BR112019020451A2 (pt) | composições e métodos para se direcionar e matar células-tronco positivas de câncer ?lfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento | |
| WO2015164364A2 (en) | Methods to manipulate alpha-fetoprotein (afp) | |
| WO2019173229A1 (en) | Methods for treating acute myeloid leukemia and related conditions | |
| CN103254317B (zh) | 一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用 | |
| JP2021517144A (ja) | Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ | |
| CN106893724A (zh) | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 | |
| JP2020535180A5 (enExample) | ||
| ES2984592T3 (es) | Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2 |